Your browser doesn't support javascript.
loading
Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders.
Gendron, Tania F; Heckman, Michael G; White, Launia J; Veire, Austin M; Pedraza, Otto; Burch, Alexander R; Bozoki, Andrea C; Dickerson, Bradford C; Domoto-Reilly, Kimiko; Foroud, Tatiana; Forsberg, Leah K; Galasko, Douglas R; Ghoshal, Nupur; Graff-Radford, Neill R; Grossman, Murray; Heuer, Hilary W; Huey, Edward D; Hsiung, Ging-Yuek R; Irwin, David J; Kaufer, Daniel I; Leger, Gabriel C; Litvan, Irene; Masdeu, Joseph C; Mendez, Mario F; Onyike, Chiadi U; Pascual, Belen; Ritter, Aaron; Roberson, Erik D; Rojas, Julio C; Tartaglia, Maria Carmela; Wszolek, Zbigniew K; Rosen, Howard; Boeve, Bradley F; Boxer, Adam L; Petrucelli, Leonard.
Afiliación
  • Gendron TF; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL 32224, USA. Electronic address: Gendron.Tania@mayo.edu.
  • Heckman MG; Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL 32224, USA.
  • White LJ; Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Veire AM; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Pedraza O; Department of Psychiatry & Psychology, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Burch AR; Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Bozoki AC; Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Dickerson BC; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Domoto-Reilly K; Department of Neurology, University of Washington, Seattle, WA 98104, USA.
  • Foroud T; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  • Forsberg LK; Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
  • Galasko DR; Parkinson and Other Movement Disorder Center, Department of Neuroscience, University of California, San Diego, La Jolla, CA 92037, USA.
  • Ghoshal N; Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Graff-Radford NR; Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Grossman M; Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Heuer HW; Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Huey ED; Department of Psychiatry, Taub Institute, Columbia University, New York, NY 10032, USA; Department of Neurology, Taub Institute, Columbia University, New York, NY 10032, USA.
  • Hsiung GR; Centre for Brain Health, Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
  • Irwin DJ; Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Kaufer DI; Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Leger GC; Parkinson and Other Movement Disorder Center, Department of Neuroscience, University of California, San Diego, La Jolla, CA 92037, USA.
  • Litvan I; Parkinson and Other Movement Disorder Center, Department of Neuroscience, University of California, San Diego, La Jolla, CA 92037, USA.
  • Masdeu JC; Nantz National Alzheimer Center, Stanley H. Appel Department of Neurology, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX 77030, USA.
  • Mendez MF; Department of Neurology, University of California at Los Angeles, Los Angeles, CA 90095, USA; Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA 90095, USA.
  • Onyike CU; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Pascual B; Nantz National Alzheimer Center, Stanley H. Appel Department of Neurology, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX 77030, USA.
  • Ritter A; Neurological Institute, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV 89106, USA.
  • Roberson ED; Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Rojas JC; Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Tartaglia MC; Krembil Brain Institute, Tanz Centre for Research in Neurodegenerative Diseases, Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Wszolek ZK; Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Rosen H; Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Boeve BF; Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
  • Boxer AL; Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Petrucelli L; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL 32224, USA. Electronic address: Petrucelli.Leonard@mayo.edu.
Cell Rep Med ; 3(4): 100607, 2022 04 19.
Article en En | MEDLINE | ID: mdl-35492244
ABSTRACT
Frontotemporal dementia (FTD) therapy development is hamstrung by a lack of susceptibility, diagnostic, and prognostic biomarkers. Blood neurofilament light (NfL) shows promise as a biomarker, but studies have largely focused only on core FTD syndromes, often grouping patients with different diagnoses. To expedite the clinical translation of NfL, we avail ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study resources and conduct a comprehensive investigation of plasma NfL across FTD syndromes and in presymptomatic FTD mutation carriers. We find plasma NfL is elevated in all studied syndromes, including mild cases; increases in presymptomatic mutation carriers prior to phenoconversion; and associates with indicators of disease severity. By facilitating the identification of individuals at risk of phenoconversion, and the early diagnosis of FTD, plasma NfL can aid in participant selection for prevention or early treatment trials. Moreover, its prognostic utility would improve patient care, clinical trial efficiency, and treatment outcome estimations.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Pick / Demencia Frontotemporal Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Revista: Cell Rep Med Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Pick / Demencia Frontotemporal Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Revista: Cell Rep Med Año: 2022 Tipo del documento: Article